The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure - Trial NCT05141552
Access comprehensive clinical trial information for NCT05141552 through Pure Global AI's free database. This phase not specified trial is sponsored by RenJi Hospital and is currently Recruiting. The study focuses on Hemodialysis Complication. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
RenJi Hospital
Timeline & Enrollment
N/A
Jan 03, 2022
Jul 31, 2022
Primary Outcome
the number of patients with hypoglycemia or urinary tract infection
Summary
SGLT2 inhibitor is a new type of sugar-lowering medicine and is recommended to treat heart
 failure. eGFR lower than 30ml/min/1.73M2 is contraindication of SGLT2 inhibitor. Heart
 failure is one of the most frequency CVD events for hemodialysis patients. But hemodialysis
 patient is unable to be treated with SGLT2 inhibitors as the contraindication. However,
 solute and fluid clearance are dependent on dialysis, but not renal function in hemodialysis
 patients. There is no data of SGLT2 inhibitor on hemodialysis patients. The aim of the
 present study is evaluate the safety of Dapagliflozin in hemodialysis patients with heart
 failure.
 
 This is a randomized, control, open study. 20 hemodialysis patients with heart failure will
 be recruited. 10 of 20 subjects will be treated with dapagliflozin 10mg everyday for 12
 weeks. The primary outcome is the number of patients with hypoglycemia or urinary infection.
 The secondary outcomes is the changes of NT-.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05141552
Non-Device Trial